Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Cognitive Function in Schizophrenia
NCT00320736Phase 4Completed
- Sponsor
- North Suffolk Community Services
- Start
- Jan 2004
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of galantamine in schizophrenia, schizoaffective disorder, sponsored by North Suffolk Community Services. Started Jan 2004; status: completed.
02
Drugs
galantamine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00320736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320736.